Technical Analysis for LXEO - Lexeo Therapeutics, Inc.

Grade Last Price % Change Price Change
C 17.00 4.94% 0.80
LXEO closed up 4.94 percent on Monday, June 24, 2024, on 1.42 times normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Down

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup 4.94%
Volume Surge Other 4.94%
NR7 Range Contraction 4.94%
NR7-2 Range Contraction 4.94%
Oversold Stochastic Weakness 4.94%
NR7 Range Contraction 8.42%

   Recent Intraday Alerts

Alert Time
Possible Pocket Pivot about 14 hours ago
10 DMA Resistance about 15 hours ago
Up 5% about 17 hours ago
20 DMA Resistance about 18 hours ago
Rose Above 20 DMA about 18 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lexeo Therapeutics, Inc. Description

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Rare Diseases Gene Therapy Applied Genetics Cardiomyopathy Lipid Storage Disorders Ataxia Friedreich's Ataxia

Is LXEO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 22.33
52 Week Low 9.0
Average Volume 160,692
200-Day Moving Average 0.00
50-Day Moving Average 14.59
20-Day Moving Average 16.79
10-Day Moving Average 17.14
Average True Range 1.14
RSI (14) 55.75
ADX 34.92
+DI 24.43
-DI 16.28
Chandelier Exit (Long, 3 ATRs) 15.71
Chandelier Exit (Short, 3 ATRs) 17.96
Upper Bollinger Bands 18.93
Lower Bollinger Band 14.65
Percent B (%b) 0.55
BandWidth 25.49
MACD Line 0.50
MACD Signal Line 0.75
MACD Histogram -0.2464
Fundamentals Value
Market Cap 452.97 Million
Num Shares 26.6 Million
EPS
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.61
Resistance 3 (R3) 18.49 17.84 18.34
Resistance 2 (R2) 17.84 17.43 17.90 18.25
Resistance 1 (R1) 17.42 17.18 17.63 17.54 18.16
Pivot Point 16.77 16.77 16.87 16.83 16.77
Support 1 (S1) 16.35 16.36 16.56 16.47 15.84
Support 2 (S2) 15.70 16.11 15.76 15.75
Support 3 (S3) 15.28 15.70 15.66
Support 4 (S4) 15.40